The FDA has declared the shortage of tirzepatide, a popular weight-loss drug, resolved. However, semaglutide, another weight-loss medication, remains in short supply. This development raises questions about the long-term viability of compounded GLP-1 treatments, with Hims & Hers Health, a provider of compounded GLP-1s, seeing continued strong demand, but facing investor concerns.
The NHS in England is planning a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to see significant clinical outcomes. The drug, which has shown impressive results in trials, will be made available through community-based services and digital health platforms, with the goal of reaching 240,000 people over the first three years. The plan is currently under consultation, with final guidance from NICE expected later this year.
